CancerGen's First Comparative Effectiveness Trial to Study Oncotype DX in Node-Positive Breast Cancer

The Center for Comparative Effectiveness Research in Cancer Genomics expects its first clinical trial, which is investigating the predictive value of Genomic Health's Oncotype Dx in node-positive breast cancer patients, to serve as a model for future comparative effectiveness studies looking at genomic technologies in cancer.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.